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Background: Atherosclerosis and cancer share multiple disease pathways. Yet, it
is unclear if atherosclerosis is associated with a subsequent higher cancer risk. We
determined the association of atherosclerotic calcification in the aortic arch, as proxy
for systemic atherosclerosis, with the risk of cancer.
Methods: Between 2003 and 2006, 2,404 participants (mean age: 69.5 years, 52.5%
women) from the prospective population-based Rotterdam Study underwent computed
tomography to quantify calcification in the aortic arch. Participants were followed for the
onset of cancer, death, loss to follow-up, or January 1st, 2015, whichever came first. We
computed sex-specific tertiles of aortic arch calcification volumes. Next, we examined
the association between the volume and severity (i.e., tertiles) of aortic arch calcification
and the risk of cancer using Cox proportional hazard models.
Results: During a median (interquartile range) follow-up of 9.6 years (8.9–10.5), 348
participants were diagnosed with cancer. Participants with the greatest severity of aortic
arch calcification had a higher risk of cancer [hazard ratio for the third tertile compared
to the first tertile of aortic arch calcification volume in the total population is 1.39 (95% CI
= 1.04–1.86)].
Conclusions: Individuals with the most severe aortic arch calcification had a higher risk
of cancer. While this could reflect the impact of long-term exposure to shared risk factors,
it might also point toward the co-occurrence of both conditions.
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INTRODUCTION
Cardiovascular diseases and cancer remain the leading causes of morbidity and mortality
worldwide (1, 2). Several studies have shown that patients with cancer are at higher risk of
developing cardiovascular disease (3, 4). This may be due to a cancer-induced hypercoagulable
state (5), or as a consequence of the detrimental effects of cancer treatment on the vascular system
(4, 6, 7). Additionally, it has also been proposed that atherosclerosis, the most important underlying
condition of cardiovascular events, and cancer may share a common pathophysiology (8).
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Common risk factors such as age, smoking, obesity, and
genetic susceptibility are known to contribute to the risk of
both atherosclerosis and cancer. Specific molecular pathways
leading to atherosclerosis, including inflammation, oxidative
stress, and uncontrolled cell proliferation, are also involved in
the pathogenesis of cancer (9, 10). As such, both diseases are
likely to co-occur. Although many studies have focused on
the presence of atherosclerosis after cancer diagnosis, less is
known about the presence and extent of atherosclerosis before
cancer manifestation. This is of particular interest, since the
first atherosclerotic lesions may already develop during infancy
(11). Understanding the sequence and timing between these
potentially interconnected diseases is pivotal as it may help to
identify high-risk patients and to develop preventive strategies
for both diseases.
Due to the central anatomical location in the arterial
system, the presence and amount of atherosclerosis in the
aortic arch may provide an easy measurable proxy of the
systemic burden of atherosclerosis within an individual. As
such, aortic arch atherosclerosis has repeatedly been linked to
mortality, in particular also of non-cardiovascular origin, of
which cancer represents a substantial part (12, 13). Hence, to
further investigate the link between atherosclerosis and cancer,
we determined the association between aortic arch calcification—
as proxy for systemic atherosclerosis—with the subsequent risk
of cancer within the setting of a large prospective population-
based study.
METHOD
Setting
This study is embedded within the Rotterdam Study, a
prospective population-based cohort study that investigates
determinants and occurrence of chronic diseases in the middle-
aged and elderly population. The design of the Rotterdam
Study has been described in detail previously (14). At study
entry, all participants were interviewed at home by a trained
research assistant, followed by two visits to the research facility to
undergo different examinations including laboratory assessments
and imaging. Follow-up examinations take place every 3 to
5 years.
Study Population
For the present study, we used the follow-up visit between
2003 and 2006 as baseline, because during this period,
participants who visited the research center were invited to
undergo non-contrast multi-detector computed tomography
(MDCT) scanning of the aortic arch as part of a project
of visualizing arterial calcification (15). We scanned 2,524
participants (response rate, 78%). Out of 2,524 scans, 6 scans were
ungradable for aortic arch calcification because of the presence
of image artifacts, leaving a total of 2,518 complete examinations
with information on calcification. We excluded participants with
a history of cancer (n = 114), resulting in 2,404 participants for
analysis. The follow-up for cancer took place continuously and
was completed for this study until January 1st, 2015.
The Rotterdam Study has been approved by the Medical
Ethics Committee of the ErasmusMC (registration numberMEC
02.1015) and by the Dutch Ministry of Health, Welfare and
Sport (Population Screening ActWBO, license number 1071272-
159521-PG). The Rotterdam Study has been entered into the
Netherlands National Trial Register (NTR; www.trialregister.nl)
and into theWHO International Clinical Trials Registry Platform
(ICTRP; www.who.int/ictrp/network/primary/en/) under shared
catalog number NTR6831. All participants provided written
informed consent to participate in the study and to have their
information obtained from treating physicians.
Assessment of Aortic Arch Calcification
We used a 16-slice or 64-slice MDCT scanner (Somatom
Sensation 16 or 64; Siemens, Forchheim, Germany) to perform
non-contrast CT scanning. We scanned the aortic arch using
an extra-cardiac scan that reached from the aortic arch to
the intracranial vasculature (1 cm above the sella turcica).
Detailed information on both scans is provided elsewhere (16,
17). As proxy of aortic arch atherosclerosis, we quantified
aortic arch calcification on the extra-cardiac scan by including
all calcification from the origin of the aortic arch (defined
as the image in which the ascending and descending aorta
merge into the inner curvature of the aortic arch) to the
first 1 cm of the branches originating from the arch (18).
Calcification volumes were calculated using dedicated software
(Syngo Calcium Scoring; Siemens, Forchheim, Germany) and
expressed in mm3.
Assessment of Cancer
Diagnoses of cancer were based on medical records of general
practitioners (including hospital discharge letters) and through
linkage with Dutch Hospital Data, the Netherlands Cancer
Registry, and histology and cytopathology registries in the
region. Incident cancer was defined as any primary malignant
tumor, excluding non-melanoma skin cancer. Only pathology-
confirmed cancers were included in analysis to exclude
the possibility of false-positive cancer diagnoses. Diagnoses
were coded independently by two physicians according to
the International Classification of Diseases, Tenth Revision
(ICD-10). In case of discrepancy, consensus was sought
through consultation with a physician specialized in internal
medicine. Date of diagnosis was based on date of biopsy
(solid tumors) and laboratory assessment (hematologic tumors),
or—if unavailable—date of hospital admission or discharge
letter. Follow-up of cancer registration was complete until
January 1st, 2015.
Measurement of Covariables
Information on educational level, smoking behavior, and
use of antidiabetic, antihypertensive, lipid-lowering, and
antithrombotic medication was obtained by trained interviewers.
Educational level was classified into primary education, lower
education (lower/intermediate general education or lower
vocational education), intermediate education (intermediate
vocational education or higher general education), or higher
education (higher vocational education or university). Smoking
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status was categorized as never, current, or former. At the
research center, height and weight were measured from which
the body mass index (BMI; kg/m2) was computed. Furthermore,
systolic and diastolic blood pressures were measured twice on
the right arm with a random-zero sphygmomanometer of which
the mean was used for analyses. Hypertension was defined as
a systolic blood pressure of ≥140mm Hg, a diastolic blood
pressure of ≥90mm Hg, or use of antihypertensive medication
(19). Hypercholesterolemia was defined as use of lipid-lowering
medication or serum total cholesterol >6.5 mmol/L. Diabetes
mellitus was defined as use of antidiabetic medication, fasting
serum glucose level ≥7.1 mmol/L, or random serum glucose
level ≥11.1 mmol/L (20). We defined history of cardiovascular
disease as history of myocardial infarction, stroke, percutaneous
transluminal coronary angioplasty, and/or coronary artery
bypass graft (21–23). Granulocyte count was measured using
the COULTER R© Ac·T diff2TM Hematology Analyzer (Beckman
Coulter, San Diego, California, USA).
Statistical Analysis
Considering the skewed distribution of aortic arch calcification
volumes, we performed a natural log-transformation and added
1 mm3 to each non-transformed volume to deal with calcium
scores of 0 (Ln[calcification volume+ 1.00 mm3]). First, we used
Cox proportional hazard models to determine the association
between aortic arch calcification [per 1-standard deviation (SD)
increase] and the subsequent risk of cancer. Model 1 was
adjusted for age at MDCT scan and sex. To investigate to
which extent any association would be driven by shared risk
factors, model 2 was additionally adjusted for shared risk factors
including educational level, smoking status, BMI, hypertension
(24), hypercholesterolemia (25), diabetes mellitus, history of
cardiovascular disease, and granulocyte count. We chose to
use granulocyte count as markers of inflammation, since these
blood cells in particular are related to larger volumes of arterial
calcification (26).
Second, we computed tertiles of calcification severity and
investigated associations with the risk of cancer, using the same
two Cox proportional hazard models as described above and
using the first tertile as reference category. As calcification
volumes were larger in men than in women, the tertiles were
computed sex-specifically. Also, considering differences in risk
factors for atherosclerosis and cancer between men and women
(27), we performed analyses stratified by sex.
For all Cox proportional hazard models, follow-up time was
used as timescale and started at date of MDCT scan until date
of incident cancer, death, loss to follow-up, or January 1st,
2015, whichever came first. Censoring participants at date of
death allowed us to compute cause-specific hazard ratios (HRs).
The proportional hazards assumption was met for all analyses
(Schoenfeld residuals test, all P > 0.05).
To explore the robustness of our findings, we performed
several sensitivity analyses to assess potential bias associated with
mortality given the strong association between atherosclerosis
and mortality (13). First, we restricted the analyses to shorter
follow-up periods to limit the number of mortality events. To this
end, participants with longer follow-up duration were censored
at, respectively, 2, 3, 4, and 5 years after the MDCT scan. Second,
we repeated the continuous analyses for themost common cancer
types, i.e., breast cancer (among women), prostate cancer (among
men), colorectal cancer, and lung cancer. Third, we stratified
analyses by use of lipid-lowering and antithrombotic medication,
and by median granulocyte count. In addition, we formally
tested interaction by adding multiplicative interaction terms to
the model.
To account for missing data of covariables (maximum amount
of missing data: 5.9%), we used multiple imputation (n =
five imputations) by chained equations along with age, sex,
calcification volumes, cardiovascular risk factors, and cancer
incidence. Statistical analyses were performed using STATA
v.15 (StataCorp).
RESULTS
Characteristics of participants at time of MDCT scan are
presented in Table 1. In addition, population characteristics
stratified by tertiles of aortic arch calcification volumes are
shown in Supplementary Table 1. The mean (SD) age was
69.5 years (6.8), and 52.5% were women. Among participants
in the highest tertile of aortic arch calcification, a higher
prevalence of cardiovascular risk factors was observed
than in participants in the lowest tertile. During a median
(interquartile range) follow-up of 9.6 years (8.9–10.5),
348 out of 2,404 participants were diagnosed with cancer,
and 463 participants died. The most frequently diagnosed
cancer types were prostate (39.2% among men), breast
(34.4% among women), colorectal (16.1% overall), and lung
(11.5% overall).
We found no statistically significant association between
continuous volumes of aortic arch calcification and the risk of
cancer (Table 2). When investigating tertiles of calcification, we
found that severe calcification was associated with a higher risk
of cancer in the total population and in men (adjusted HR for the
third tertile compared to the first tertile of aortic arch calcification
in total population = 1.39, 95% CI = 1.04–1.86 and in men =
1.44, 95% CI = 1.00–2.09). This association was also observed
in women, albeit not statistically significant (HR = 1.33, 95% CI
= 0.83–2.13). Effect estimates were slightly attenuated when we
corrected for different cardiovascular risk factors.
When censoring participants with a follow-up duration longer
than 2 years, we found that effect estimates were higher for both
continuous aortic arch calcification volume as well as for severe
calcification, albeit not statistically significant (adjusted HR per
1-SD increase in aortic calcification = 1.24, 95% CI = 0.90–
1.71, and adjusted HR for the third tertile compared to the first
tertile of aortic arch calcification = 1.53, 95% CI = 0.75–2.13).
The effect estimates decreased with inclusion of longer follow-up
duration (Table 3).
Regarding specific cancer types, we found that among women,
aortic arch calcification was associated with a lower risk of breast
cancer (HR per 1-SD increase in aortic arch calcification = 0.71,
95% CI = 0.52–0.98) and with a higher risk of lung cancer in the
total population (HR= 2.35, 95% CI= 1.39–3.96, Table 4).
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TABLE 1 | Characteristics of the study population.
Characteristic All participants
(N = 2,404)
Men
(N = 1,143)
Women
(N = 1,261)
Age* 69.5 (6.8) 69.6 (6.6) 69.5 (6.9)
Educational level
Primary 198 (8.2) 70 (6.1) 128 (10.2)
Lower 1023 (42.6) 298 (26.1) 725 (57.5)
Intermediate 737 (30.7) 444 (38.8) 293 (23.2)
Higher 446 (18.6) 331 (29.0) 115 (9.1)
Body mass index* 27.7 kg/m2 (4.1) 27.4 kg/m2 (3.5) 27.9 kg/m2 (4.5)
Smoking
Never 687 (28.6) 157 (13.7) 530 (42.0)
Former 1339 (55.7) 777 (68.0) 562 (44.6)
Current 378 (15.7) 209 (18.3) 169 (13.4)
Hypertension
No 604 (25.1) 283 (24.8) 321 (25.5)
Yes 1800 (74.9) 860 (75.2) 940 (74.5)
Hypercholesterolemia
No 1387 (57.7) 721 (63.1) 666 (52.8)
Yes 1017 (42.3) 422 (36.9) 595 (47.2)
Lipid-lowering
medication use
No 1806 (75.1) 851 (74.5) 955 (75.7)
Yes 598 (24.9) 292 (25.5) 306 (24.3)
Antithrombotic
medication use
No 1813 (75.4) 794 (69.5) 1019 (80.8)
Yes 591 (24.6) 349 (30.5) 242 (19.2)
Diabetes mellitus
No 2076 (86.4) 973 (85.1) 1103 (87.5)
Yes 328 (13.6) 170 (14.9) 158 (12.5)
History of
cardiovascular disease
No 2108 (87.7) 939 (82.2) 1169 (92.7)
Yes 296 (12.3) 204 (17.8) 92 (7.3)
Granulocyte count† 3.8 (3.0–4.6) 4.0 (3.2–4.8) 3.6 (2.9–4.4)
Aortic arch calcification† 263.8 mm3
(46.5–883.2)
296.9 mm3
(52.9–1009.5)
228.5 mm3
(41.8–825.0)
Characteristics are measured at time of MDCT scan. Data are presented as frequency
(percent) unless indicated otherwise. Numbers are shown after multiple imputation.
*Presented as mean (standard deviation).
†
Presented as median (interquartile range).
No effect modification was observed by lipid-lowering and
antithrombotic medication use and by median granulocyte
count. All interactions were tested on the multiplicative scale and
did not reach statistical significance (P > 0.05).
DISCUSSION
In this population-based study, we found that only individuals
with the most severe aortic arch calcification had a higher risk of
cancer, in particular in the short term.
TABLE 2 | The association between aortic arch calcification and the risk of cancer.
Risk of cancer
Aortic arch
calcification
n/N Model I
HR (95% CI)
Model II
HR (95% CI)
348/2,404
Total
population
Per 1-SD
increase*
1.12 (0.99–1.27) 1.09 (0.96–1.24)
T1 107/802 Ref. Ref.
T2 98/801 0.91 (0.69–1.20) 0.89 (0.67–1.18)
T3 143/801 1.48 (1.12–1.95) 1.39 (1.04–1.86)
131/1,261
Women Per 1-SD
increase*
1.10 (0.90–1.33) 1.05 (0.88–1.28)
T1 41/421 Ref. Ref.
T2 35/420 0.85 (0.54–1.34) 0.82 (0.52–1.30)
T3 55/420 1.45 (0.93–2.27) 1.33 (0.83–2.13)
217/1,143
Men Per 1-SD
increase*
1.14 (0.97–1.33) 1.12 (0.96–1.32)
T1 66/381 Ref. Ref.
T2 63/381 0.95 (0.67–1.35) 0.94 (0.66–1.34)
T3 88/381 1.49 (1.04–2.12) 1.44 (1.00–2.09)
Hazard ratios in model I are adjusted for age (and sex in the total population). Hazard ratios
in model II are adjusted for covariates in model I plus adjustment for education, smoking
status, body mass index, hypertension, hypercholesterolemia, diabetes mellitus, history
of cardiovascular disease, and granulocyte count.
CI, confidence interval; HR, hazard ratio; n, number of participants with incident cancer;
N, total number for participants; T, tertile.
*Ln(calcification volume + 1 mm3 )–transformed volumes.
It has previously been shown that atherosclerosis and
cardiovascular events occur after cancer diagnosis potentially
as a result of cancer itself—by inducing a hypercoagulable
state—and cancer treatment. Based on the shared risk factors
and pathophysiology, we hypothesized that atherosclerosis is
also associated with a subsequent higher risk of cancer and
that the strength of this association would diminish after
adjustment for shared risk factors. When investigating the
association between the amount of aortic arch calcification
and the risk of cancer, we found only a slightly higher risk,
which was not statistically significant. However, when targeting
the group of individuals in the highest tertile of calcification,
we found 39% increase of the risk of cancer compared to
those with the lowest tertile. Further investigation of this
association demonstrated that the effect of atherosclerosis on
cancer seems to be largest in the short term (during the
first 2 years of follow-up). Although this indicates that severe
atherosclerosis may be present before cancer diagnosis, it might
also reflect reverse causation. It is possible that subclinical cancer
development already influences the course of atherosclerosis.
Since both atherosclerosis and cancer are conditions with a long
preclinical phase, we cannot prove causality, nor can we rule out
reverse causation.
Overall, we found no prominent differences in the association
between atherosclerosis and cancer before and after adjustment
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TABLE 3 | The association between aortic arch calcification and the risk of cancer
while censoring at different time points.
Risk of cancer
Aortic arch
calcification
n/N Model I
HR (95% CI)
Model II
HR (95% CI)
62/2,404
Restricted
to 2 years
of follow-up
Per 1-SD
increase*
1.25 (0.92–1.70) 1.24 (0.90–1.71)
T1 16/802 Ref. Ref.
T2 19/801 1.15 (0.59–2.27) 1.13 (0.57–2.24)
T3 27/801 1.59 (0.80–3.15) 1.53 (0.75–2.13)
103/2,404
Restricted
to 3 years
of follow-up
Per 1-SD
increase*
1.13 (0.90–1.43) 1.12 (0.88–1.42)
T1 28/802 Ref. Ref.
T2 30/801 1.02 (0.60–1.72) 1.01 (0.60–1.72)
T3 45/801 1.45 (0.86–2.46) 1.43 (0.83–2.47)
137/2,404
Restricted
to 4 years
of follow-up
Per 1-SD
increase*
1.04 (0.86–1.27) 1.04 (0.85–1.27)
T1 44/802 Ref. Ref.
T2 39/801 0.83 (0.53–1.29) 0.82 (0.53–1.28)
T3 54/801 1.08 (0.69–1.69) 1.06 (0.67–1.69)
183/2,404
Restricted
to 5 years
of follow-up
Per 1-SD
increase*
1.02 (0.87–1.20) 1.02 (0.87–1.21)
T1 61/802 Ref. Ref.
T2 51/801 0.80 (0.55–1.17) 0.81 (0.55–1.18)
T3 71/801 1.11 (0.75–1.62) 1.11 (0.74–1.65)
Hazard ratios in model I are adjusted for age (and sex in the total population). Hazard ratios
in model II are adjusted for covariates in model I plus adjustment for education, smoking
status, body mass index, hypertension, hypercholesterolemia, diabetes mellitus, history
of cardiovascular disease, and granulocyte count.
CI, confidence interval; HR, hazard ratio; n, number of participants with incident cancer;
N, total number for participants; T, tertile.
*Ln(calcification volume + 1 mm3 )–transformed volumes.
for cardiovascular risk factors. This suggests that overall,
traditional cardiovascular risk factors do not fully explain
potential co-occurrence of atherosclerosis and cancer. This
could point toward other factors, such as genetic variation or
exogenous factors, that may explain the differential susceptibility
to either atherosclerosis or cancer. However, exposure to shared
risk factors might explain the higher risk of cancer in those
individuals with the most severe aortic arch calcification and the
strong association with lung cancer. It is likely that individuals
who have been exposed to shared risk factors for a long period,
and in high amounts, have both the largest volumes of aortic arch
calcification and the highest risk of cancer. This suggests that the
co-occurring deterioration of atherosclerosis and development
of cancer is due to long and severe exposure to risk factors.
However, also in these individuals, the size of the effect estimates
only slightly diminished after correction for shared risk factors.
TABLE 4 | The association between aortic arch calcification and the risk of
different cancer types.
HR per 1-SD increase in aortic arch calcification*
n/N Model I
HR (95% CI)
Model II
HR (95% CI)
Breast cancer 45/1,261 0.75 (0.55–1.00) 0.71 (0.52–0.98)
Prostate cancer 72/1,143 1.08 (0.82–1.39) 1.07 (0.81–1.40)
Colorectal cancer 56/2,404 1.18 (0.86–1.63) 1.04 (0.76–1.43)
Lung cancer 40/2,404 2.87 (1.72–4.78) 2.35 (1.39–3.96)
Hazard ratios in model I are adjusted for age (and sex in the total population). Hazard ratios
in model II are adjusted for covariates in model I plus adjustment for education, smoking
status, body mass index, hypertension, hypercholesterolemia, diabetes mellitus, history
of cardiovascular disease, and granulocyte count.
CI, confidence interval; HR, hazard ratio; n, number of participants with incident cancer;
N, total number for participants.
*Ln(calcification volume + 1 mm3 )–transformed volumes.
Sex differences—reflected by differences in hormonal levels—
may also influence the apparent different impact of shared
risk factors on the development of atherosclerosis and cancer.
Aortic arch calcification was associated with a lower risk of
breast cancer in women. It has previously been proposed
that an inverse association between aortic atherosclerosis and
cancer holds in particular for cancers that are hormone-
dependent or highly affected by genetics rather than for
those caused by exogenous factors (28). Also, aortic arch
calcification in particular is strongly associated with mortality,
indicating that the inverse relation between aortic arch
calcification and cancer may partly be due to residual
survival bias (13). More in-depth inquiry on this topic
is required.
Several strengths of our study are worth mentioning.
Our study is a large prospective population-based study and
therefore less vulnerable to selection and information bias
than retrospective ones. In addition, we have prospective and
unbiased collection of many risk factors that are not available in
healthcare databases. All cancers were pathology proven, which
excludes the chance of misclassification. Also, we had an image-
based assessment of calcification volumes and standardized
ascertainment of cancer incidence.
Yet, some potential limitations need to be addressed. First,
despite sufficient power to detect a large effect size of 1.5
for all cancers (α = 0.05, β = 0.80), we acknowledge the
lack of statistical power to elaborate on specific cancer types.
Second, strong associations of atherosclerosis with the risk of
cardiovascular events and mortality may have weakened any
potential association of atherosclerosis with cancer. Nevertheless,
our finding that the most severe aortic calcification is associated
with a higher risk of cancer—while these persons have the
highest risk of mortality—might indicate that the effect of
survival is limited. Third, the burden of atherosclerosis may
influence the prognosis and course of cancer rather than
the development itself. Ideally, measures of atherosclerosis at
multiple time points are needed to also assess changes in
atherosclerotic burden before cancer diagnosis. Future studies
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are needed to unravel differences in the etiology between
atherosclerosis and cancer explained by other factors such
as genetic and exogenous factors. Lastly, calcification is only
a part of the atherosclerotic plaque. Non-calcified parts of
the plaques cannot be visualized with non-enhanced CT.
Nevertheless, it has been shown that calcification volume
is an adequate measure for the total underlying plaque
burden (29).
CONCLUSIONS
We found that only individuals with the most severe aortic arch
calcification had a higher risk of cancer, potentially through long-
term parallel exposure to shared risk factors. Other factors, such
as genetic variation or exogenous factors, may further explain
susceptibility to either atherosclerosis or cancer.
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